PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32574722-0	2020	HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.	enzalutamide	145-157	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Homo sapiens	0-6	
32574722-13	2020	CONCLUSIONS: HSD3B1 (CC) genotype was associated with shorter TTP and lower PSA response rate in mCRPC patients treated with abiraterone or enzalutamide.	enzalutamide	140-152	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Homo sapiens	13-19	
32592760-0	2020	Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean?	enzalutamide	126-138	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Homo sapiens	11-17	
32387417-2	2020	Here, we evaluated the association between the inherited HSD3B1 c.1245A>C variant and outcomes from metastatic castration-resistant prostate cancer (mCRPC) after first-line abiraterone (Abi) or enzalutamide (Enza).	enzalutamide	208-212	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Homo sapiens	57-63